Ask AI
Treating DLBCL

CME

Novel Agents, New Combinations: An Expert Overview of Unmet Needs and Emerging Therapies for DLBCL

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: January 30, 2026

Expiration: July 29, 2026

Activity

Progress
1 2
Course Completed

Introduction

In this activity, Jeremy S. Abramson, MD, MMSc, discusses contemporary treatment paradigms and novel strategies for managing diffuse large B-cell lymphoma (DLBCL).

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

How many people with DLBCL do you provide care for in a typical month?

For those who practice in academic or community settings, please indicate your practice setting:

Which of the following is a novel bispecific antibody targeting CD19 and CD3 that has shown activity in heavily pretreated DLBCL?

In your current practice, which of the following would you be most likely to recommend for a patient with previously untreated DLBCL not otherwise specified (NOS) with activated B-cell (ABC) of origin and an International Prognostic Index (IPI) score of 3 who is not frail and has no cardiovascular dysfunction?

A patient with previously untreated DLBCL and an IPI score of 5 is potentially interested in a trial of CAR T-cell therapy. During your consultation, which of the following CAR T-cell therapies would you tell him is currently being assessed in a phase III trial as first-line therapy for patients with DLBCL and an IPI score of 4-5?